Login / Signup

Assessment and clinical utility of pharmacogenomics by healthcare practitioners in North Carolina.

Brianne S RaccorDorothea K ThompsonChantley ThomasAmber K HillKaitlin ShieldsIsabel Alcala-WilliamsTristyn CartrettePius S FasinuAntoine Al-Achi
Published in: Pharmacogenomics (2020)
Aim: Perceived knowledge, use and perceptions of pharmacogenomics (PGx) testing were assessed among healthcare practitioners in North Carolina. Materials & methods: A validated survey was distributed to various healthcare professionals and analyzed for differences among the groups. Results: The majority of the 744 survey respondents acknowledged the perceived benefits of PGx testing, but indicated either never or rarely using it. A substantial percentage of practitioners reported educational experiences but the majority had received no training. Among groups reporting using PGx testing, barriers to implementation were cost and insufficient training. Conclusion: The perceived cost of PGx testing and insufficiency or lack of training are major contributing factors to the infrequent use of PGx testing by healthcare providers in North Carolina.
Keyphrases
  • healthcare
  • primary care
  • mental health
  • social support
  • depressive symptoms
  • physical activity
  • general practice
  • cross sectional
  • tertiary care
  • health information
  • health insurance